Sat.Apr 19, 2025

article thumbnail

Landiolol

New Drug Approvals

Landiolol 133242-30-5 ONO-1101 Ono 1101 WHO 7516 FDA APPROVED 11/22/2024, Rapiblyk , To treat supraventricular tachycardia C25H39N3O8 509.6 g/mol [(4 S )-2,2-dimethyl-1,3-dioxolan-4-yl]methyl 3-[4-[(2 S )-2-hydroxy-3-[2-(morpholine-4-carbonylamino)ethylamino]propoxy]phenyl]propanoate [(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl 3-[4-[(2S)-2-hydroxy-3-[2-(morpholine-4-carbonylamino)ethylamino]propoxy]phenyl]propanoate UNII-62NWQ924LH (S-(R*,R*))-(2,2-Dimethyl-1,3-dioxolan-4-yl)methyl 4-(2-hydroxy-

FDA 62
article thumbnail

Father's mental health can impact children for years

Science Daily: Pharmacology News

Five-year-olds exposed to paternal depression are more likely to have behavioral issues in grade school, researchers find.

Research 212
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Wildfire Survivors Still Struggle With Basic Needs and Support

Drugs.com

SATURDAY, April 19, 2025 Three months after wildfires tore through Los Angeles, a new study offers insight into the lasting needs of fire survivors. Researchers from UC Davis School of Medicine said their findings from earlier wildfires may help w.

Research 130
article thumbnail

Bioinformatic Analysis of the Protective Effects of Dexmedetomidine and Thrombopoietin Against Hypoxia/Reoxygenation‐Induced Injury in AC16 Cells

Chemical Biology and Drug Design

This diagram illustrates the protective effects of dexmedetomidine (Dex) and thrombopoietin (TPO) against hypoxia/reoxygenation (H/R)-induced injury in AC16 cells. Both treatments activate signaling pathways, including stem cell pluripotency, TNF, TGF-, and MAPK, promoting cell proliferation and inhibiting apoptosis. Dex and TPO suppress caspase-3 activity and autophagy, providing protection against cellular damage induced by H/R injury.

article thumbnail

Bridging Innovation & Patient Care: The Growing Role of AI

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

article thumbnail

Bivamelagon

New Drug Approvals

Bivamelagon CAS 2641595-54-0 NO1Y8WRA8N, 629.3 g/mol, C 35 H 53 ClN 4 O 4 MC-4R Agonist 2 N -[(3 S ,5 S )-1-[[(3 S ,4 R )-4-(4-Chlorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-5-(4-morpholinylcarbonyl)-3-pyrrolidinyl]-2-methyl- N -( cis -4-methylcyclohexyl)propanamide N -((3S,5S)-1-((3S,4R)-1-( tert -Butyl)-4-(4-chlorophenyl)pyrrolidine-3-carbonyl)-5-(morpholine-4-carbonyl)pyrrolidin-3-yl)- N -( cis -4-methylcyclohexyl)isobutyramide N -[(3 S ,5 S )-1-[(3 S ,4 R )-1- tert -butyl-4-(4-